Stock Events

Stock Events

PMV Pharmaceuticals 

$1.28
0
+$0.01+0.79% Wednesday 06:41

Statistics

Day High
1.28
Day Low
1.28
52W High
-
52W Low
-
Volume
4
Avg. Volume
-
Mkt Cap
68.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2025
Q4 2025
Next
-0.41
-0.38
-0.36
-0.33
Expected EPS
-0.41
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-117.42MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMVP.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could directly compete with PMV Pharmaceuticals' precision oncology approaches.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, potentially offering alternative treatments to those developed by PMV Pharmaceuticals.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, specifically using CRISPR technology, which could rival PMV Pharmaceuticals' cancer therapies.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics focuses on base editing, a form of gene editing that could compete with PMV Pharmaceuticals' approach to targeting cancer at the genetic level.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics specializes in allogeneic CAR T-cell therapies, which could be an alternative to PMV Pharmaceuticals' targeted cancer treatments.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics' gene editing and gene therapy technologies could offer alternatives to PMV Pharmaceuticals' precision oncology products.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is developing programmed cellular immunotherapies, which could compete with PMV Pharmaceuticals' approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR T-cell therapy, competing in the oncology space with PMV Pharmaceuticals.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies but is expanding into gene therapy, potentially competing in the broader biotech space with PMV Pharmaceuticals.

About

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Show more...
CEO
ISIN
US69353Y1038

Listings

XNAS
US
PMVP
BOATS
BOATS
PMVP.BOATS

0 Comments

Share your thoughts

FAQ

What is PMV Pharmaceuticals stock price today?▼
The current price of PMVP.BOATS is $1.28 USD — it has increased by +0.79% in the past 24 hours. Watch PMV Pharmaceuticals stock price performance more closely on the chart.
What is PMV Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange PMV Pharmaceuticals stocks are traded under the ticker PMVP.BOATS.
What is PMV Pharmaceuticals market cap?▼
Today PMV Pharmaceuticals has the market capitalization of 68.11M
When is the next PMV Pharmaceuticals earnings date?▼
PMV Pharmaceuticals is going to release the next earnings report on May 08, 2026.
What were PMV Pharmaceuticals earnings last quarter?▼
PMVP.BOATS earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.4 USD resulting in a +16.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PMV Pharmaceuticals revenue for the last year?▼
PMV Pharmaceuticals revenue for the last year amounts to 0 USD.
What is PMV Pharmaceuticals net income for the last year?▼
PMVP.BOATS net income for the last year is -117.42M USD.
When did PMV Pharmaceuticals complete a stock split?▼
PMV Pharmaceuticals has not had any recent stock splits.